Novo Nordisk has made another major capital investment in production capacity for its diabetes and obesity therapies, agreeing to spend €2.1 billion ($2.3 billion) on a fa
Novo Nordisk’s obesity therapy Wegovy has cut the risk of death by 19% in the SELECT trial, mirroring the benefits of the drug in cardiovascular outcomes in people who are
Novo Nordisk is leaving nothing to chance when it comes to claiming a stake in the burgeoning market for diabetes and obesity therapies, announcing a plan to spend a whopp
Novo Nordisk is finally facing some major competition to its obesity franchise juggernaut, now that Eli Lilly’s rival therapy tirzepatide has been approved by the FDA as a
Sales of Novo Nordisk’s fast-growing GLP-1 agonist drugs for diabetes and obesity may be held back by supply constraints, but feverish demand is still driving strong growt
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl
